变构调节
CXCR3型
功能选择性
化学
G蛋白偶联受体
变构调节剂
受体
趋化因子受体
配体(生物化学)
趋化因子受体
C-C趋化因子受体6型
CXCL14型
信号转导
趋化因子
细胞生物学
生物
生物化学
作者
Viachaslau Bernat,Regine Brox,Markus R. Heinrich,Yves P. Auberson,Nuška Tschammer
出处
期刊:ChemMedChem
[Wiley]
日期:2015-02-05
卷期号:10 (3): 566-574
被引量:20
标识
DOI:10.1002/cmdc.201402507
摘要
Abstract Over the last decade, functional selectivity (or ligand bias) has evolved from being a peculiar phenomenon to being recognized as an essential feature of synthetic ligands that target G protein‐coupled receptors (GPCRs). The CXC chemokine receptor 3 (CXCR3) is an outstanding platform to study various aspects of biased signaling, because nature itself uses functional selectivity to manipulate receptor signaling. At the same time, CXCR3 is an attractive therapeutic target in the treatment of autoimmune diseases and cancer. Herein we report the discovery of an 8‐azaquinazolinone derivative ( N ‐{1‐[3‐(4‐ethoxyphenyl)‐4‐oxo‐3,4‐dihydropyrido[2,3‐ d ]pyrimidin‐2‐yl]ethyl}‐4‐(4‐fluorobutoxy)‐ N ‐[(1‐methylpiperidin‐4‐yl)methyl]butanamide, 1 b ) that can inhibit CXC chemokine 11 (CXCL11)‐dependent G protein activation over β‐arrestin recruitment with 187‐fold selectivity. This compound also demonstrates probe‐dependent activity, that is, it inhibits CXCL11‐ over CXCL10‐mediated G protein activation with 12‐fold selectivity. Together with a previously reported biased negative allosteric modulator from our group, the present study provides additional information on the molecular requirements for allosteric modulation of CXCR3.
科研通智能强力驱动
Strongly Powered by AbleSci AI